Carbylan Therapeutics (CBYL) Tops Q3 EPS by 7c

Carbylan Therapeutics (NASDAQ: CBYL) reported Q3 EPS of ($0.19), $0.07 better than the analyst estimate of ($0.26).

For earnings history and earnings-related data on Carbylan Therapeutics (CBYL) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Investing.com’s stocks of the week
• BMO starts chip stocks coverage: Here are its preferred picks